NCT05615623View on ClinicalTrials.gov

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 4, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2026

Conditions

Brain Tumor

Interventions

DEVICE

Exablate

Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors

DRUG

Doxorubicin

Doxorubicin infusion

Trial Locations (1)

M4N 3M5

RECRUITING

Sunnybrook Research Institute, Toronto